AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.

The pre-print results, from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health, showed one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta and Gamma COVID-19 variants.

On top of that, AZ’s jab showed high efficacy against the Delta and Alpha variants, showing an 87% reduction and 90% reduction of hospitalisations or deaths respectively.

One dose of Vaxzevria had lower efficacy against milder symptomatic disease than against severe disease, although AZ added that the indicated two dose schedule of the vaccine is known to enhance efficacy in this disease setting.

The vaccine’s effectiveness against any symptomatic disease was 50% for the Beta or Gamma variants, and 70% and 72% against the Delta and Alpha variants respectively.

The analysis included 69,533 individuals who tested positive for COVID-19 from December 2020 to May 2021 in Ontario, Canada, with 28,705 testing positive for non-variants of concern and 40,828 testing positive for a variant of concern.

“With different variants threatening to disrupt our route out of the pandemic, this real-world evidence shows that Vaxzevria, along with other vaccines used in Canada, provides a high level of protection against the most serious forms of the disease, even after just one shot,” Said Mene Pangalos, executive vice president, BioPharmaceuticals R&D at AZ.

“It is essential that we continue to protect as many people as possible in all corners of the world in order to get ahead of this deadly virus,” he added.

Reference
https://www.pharmatimes.com/news/az_says_its_covid-19_vaccine_protects_against_severe_disease_caused_by_variants_1373488

More News
U.S. Tariffs Update – May 2025!
News · 02/06/2025

The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.

READ MORE
Major Regulatory Changes in 2025
News · 02/05/2025

In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.

READ MORE
Technologies And Strategies Reshaping Regulatory Trends
News · 02/05/2025

The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.

READ MORE
Biomanufacturing proliferates in chemicals
News · 31/03/2025

In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?

READ MORE
New Trump tariffs worry North American chemical industries
News · 31/03/2025

High duties on imports from Canada, Mexico and China raise problems for international supply chains.

READ MORE
Advanced Drug Delivery Systems
News · 01/03/2025

Advanced Drug Delivery Systems Market, valued at USD 234.84 billion in 2023, is on a trajectory of significant growth, projected to reach USD 352.01 billion by 2032

READ MORE
US FDA Bans Food Dye Red No.3
News · 01/03/2025

The U.S. Food and Drug Administration on January 15, 2025, announced its decision to ban Red Dye No. 3 also referred to as Erythrosine.

READ MORE
Emerging Trends in Microsphere Technology
News · 01/02/2025

Targeted drug delivery revolutionises treatment by focusing medications on specific tissues, reducing the impact on healthy cells. Scientists enhance this precision with carriers like microspheres and nanoparticles, controlling release and absorption. Microspheres, made from biodegradable proteins or polymers, sustain drug release, making them ideal for targeted therapies, especially in oncology. Beyond drug delivery, microspheres open new possibilities across industries—from next-gen coatings to thermal insulation. With tailored sizes, shapes, and materials, they drive advancements in pharmaceuticals, advanced materials, and more.

READ MORE
US FDA proposes mandatory Asbestos testing in Cosmetics with Talc
News · 01/02/2025

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing cosmetics for asbestos. The FDA noted that this move aims to protect consumers from potential harm posed by asbestos, a known carcinogen linked to serious illnesses such as lung and ovarian cancers.

READ MORE